These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17693620)

  • 1. When to stop treatment arms in a clinical trial assessing time to event with more than two arms against a common control.
    Grobler AC; Carrara HR; Mwambi HG; Parker RA
    Eval Health Prof; 2007 Sep; 30(3):284-99. PubMed ID: 17693620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective exclusion of treatment arms in multi-arm randomized clinical trials.
    Law MG; Emery S
    Stat Med; 2003 Jan; 22(1):19-30. PubMed ID: 12486749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size calculation in survival trials accounting for time-varying relationship between noncompliance and risk of outcome event.
    Li B; Grambsch P
    Clin Trials; 2006; 3(4):349-59. PubMed ID: 17060209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Issues with statistical risks for testing methods in noninferiority trial without a placebo ARM.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(2):201-13. PubMed ID: 17365218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal design of clinical trials comparing several treatments with a control.
    Marschner IC
    Pharm Stat; 2007; 6(1):23-33. PubMed ID: 17323312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study duration for clinical trials with survival response and early stopping rule.
    Kim K; Tsiatis AA
    Biometrics; 1990 Mar; 46(1):81-92. PubMed ID: 2350572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interim analysis in clinical trials: a methodological guide].
    Muñoz Navarro SR; Bangdiwala SI
    Rev Med Chil; 2000 Aug; 128(8):935-41. PubMed ID: 11129556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adding new experimental arms to randomised clinical trials: Impact on error rates.
    Choodari-Oskooei B; Bratton DJ; Gannon MR; Meade AM; Sydes MR; Parmar MK
    Clin Trials; 2020 Jun; 17(3):273-284. PubMed ID: 32063029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian clinical trials.
    Berry DA
    Nat Rev Drug Discov; 2006 Jan; 5(1):27-36. PubMed ID: 16485344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring pairwise comparisons in multi-armed clinical trials.
    Follmann DA; Proschan MA; Geller NL
    Biometrics; 1994 Jun; 50(2):325-36. PubMed ID: 8068834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Content analysis of local newspaper coverage of the microbicide trials in South Africa.
    Cooper S; Anafi P; Sun C; Naidoo N; Reddy P; Buchanan D
    Int Q Community Health Educ; 2008-2009; 29(2):105-21. PubMed ID: 19546087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global benefit-risk assessment in designing clinical trials and some statistical considerations of the method.
    Pritchett YL; Tamura R
    Pharm Stat; 2008; 7(3):170-8. PubMed ID: 17538942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A note on the conservativeness of the confidence interval approach for the selection of non-inferiority margin in the two-arm active-control trial.
    Sankoh AJ
    Stat Med; 2008 Aug; 27(19):3732-42. PubMed ID: 18407575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical considerations on design and analysis of bridging and multiregional clinical trials.
    Tsong Y
    J Biopharm Stat; 2012 Sep; 22(5):1078-80. PubMed ID: 22946952
    [No Abstract]   [Full Text] [Related]  

  • 15. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pairwise multiple comparison adjustment in survival analysis.
    Logan BR; Wang H; Zhang MJ
    Stat Med; 2005 Aug; 24(16):2509-23. PubMed ID: 15977296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated confidence intervals for adaptive group sequential trials.
    Mehta CR; Bauer P; Posch M; Brannath W
    Stat Med; 2007 Dec; 26(30):5422-33. PubMed ID: 17918195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the statistical power for multiple tests: a case study.
    Yeo A; Qu Y
    Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
    Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
    Trials; 2011 Mar; 12():81. PubMed ID: 21418571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.